Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial.

Xia MengAnxin WangGuojun ZhangSiying NiuWei LiSifei HanFang FangXingquan ZhaoKehui DongZening Jin Huaguang ZhengKelin ChenHao Li Chengyuan Yang Yong-Jun Wang

Published in: Stroke and vascular neurology (2021)

Our data suggest that the GMEX system is a reliable and feasible point-of-care system for rapid CYP2C19 genotyping for the CHANCE-2 trial or related clinical and research applications.

Keyphrases

phase iii
study protocol
phase ii
genome wide
high throughput
clinical trial
loop mediated isothermal amplification
randomized controlled trial
electronic health record
genetic diversity
big data
dna methylation
gene expression
artificial intelligence